Response of the clinically uninvolved skin of psoriatic patients to repeated tape stripping during cyclosporin A treatment

British Journal of Dermatology

Volumn 130, Issue 2, 1994, Pages 181-188

  GERRITSEN, M J P ^a   RULO, H F C ^a   ARNOLD, W P ^a   VAN DE KERKHOF, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE;

CELL ADHESION MOLECULES, NEURONAL; CELL DIFFERENTIATION; CELL DIVISION; CYCLOSPORINE; EPIDERMIS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; KERATINOCYTES; KI-67 ANTIGEN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN PRECURSORS; PSORIASIS; T-LYMPHOCYTES; TENASCIN;

EID: 0028334773     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1994.tb02897.x     Document Type: Article

References (63)

1. Drug transforms transplant medicine. Cyclosporin obviates rejection problems with organ transplants and may also be used to treat autoimmune disease and parasitic infections
2. Cyclosporine: a new immunosuppressive agent for organ transplantation
3. Cyclosporin A for psoriasis
4. Cyclosporin for psoriasis
5. Cyclosporin and psoriasis
6. Short‐term use of cyclosporin A in severe psoriasis
7. Clearance of psoriasis with low dose cyclosporin
8. Cyclosporine improves psoriasis in a double‐blind study
9. Psoriasis
10. Cyclosporin A treatment of severe psoriasis
11. Cyclosporine in the treatment of psoriasis
12. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A
13. Response and relapse of moderate psoriasis treated with cyclosporin A
14. Low‐dose cyclosporin A in severe psoriasis. A double‐blind study
15. Biological effects of cyclosporin A: a new antilymphocytic agent
16. Intralesional cyclosporin in psoriasis: effect on T lymphocyte and dendritic cell subpopulations
17. Studies of the effect of cyclosporin in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation
18. Effects of cyclosporin A on cultured human epidermal keratinocytes. Growth and 5‐bromo‐2'‐uridine incorporation
19. Additive and synergistic antiproliferative effects of cyclosporin A and gamma Interferon on cultured human keratinocytes
20. Calmodulin content of keratino cytes in vitro: effect of proliferation and cyclosporin A
21. Effect of cyclosporin on human epidermal cells in vitro
22. 8)
23. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media
24. The effect of cyclosporin on epidermal cells. II. Cyclosporin A inhibits proliferation of normal and transformed keratinocytes
25. Cyclosporin A inhibits directly in vivo keratinocyte proliferation of living human skin
26. Cyclosporin A inhibits biological effects of tumor promoting phorbol esters
27. Cyclosporin A inhibits phorbol ester‐induced cellular proliferation and tumor promotion as well as phosphorylation of a 100‐kd protein in mouse epidermis
28. 1H‐n.m.r. and GC‐MS spectroscopy
29. Cyclosporine inhibits ornithine decarboxylase gene expression and acute Inflammation in response to phorbol ester treatment of hairless mouse skin
30. Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis
31. Cyclosporin A does not inhibit epidermal cell growth at therapeutic levels
32. Studies of the effect of cyclosporine in psoriasis in vivo: combined effect on activated T lymphocytes and epidermal regenerative maturation
33. Examination of the epidermis by the strip method of removing horny layers. I. Observations of thickness of the horny layer, and on mitotic activity after stripping
34. Examination of the epidermis by the strip method. II. Biometric data on regeneration of the human epidermis
35. Synchronized growth in human epidermis following tape‐stripping: its implication for cell kinetic studies
36. Reproducibility of clinical trials of topical glucocorticosteroids
37. 0 cells in human epidermis in vivo following tape stripping
38. Response of the clinically uninvolved skin of psoriatic patients to standardized injury
39. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
40. Two binding sites for Ki‐67 related to quiescent and cycling cells in human epidermis
41. MON‐150, a versatile monoclonal antibody against involucrin: characterization and applications
42. Immunologic cross‐reaction of stratum corneum basic protein and a keratohyalin granule protein
43. Localization of the histidinerich protein in keratohyalin: a morphologic and macromolecular marker in epidermal differentiation
44. Characterization of an epidermal phosphatase specific for filaggrin phosphorylated by casein kinase II
45. Limited proteolysis of high molecular weight histidine‐rich protein of rat epidermis by epidermis proteinases
46. Identification of proteolytic cleavage sites in the conversion of profillagrin in filaggrin in mammalian epidermis
47. Evidence for filaggrin as a component of the cell envelope of the newborn rat
48. Epidermal keratin: tilaments and matrix
49. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the Water activity of the environment
50. Filaggrin expression in normal and pathological skin
51. Abnormal distribution of epidermal protein antigens in psoriatic epidermis
52. Presence in human epidermal cells of a soluble protein precursor of the cross‐linked envelope: activation of the cross‐linking by calcium ions
53. Involucrin expression in normal and neoplastic human skin: a marker for keratinocyte differentiation
54. The keratinocyte as differentiated cell type
55. Tenascin expression in hyperproliferative skin diseases
56. Induction of tenascin in healing wounds
57. Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy
58. 3: a cell biological study
59. Enumeration of T‐cell subpopulations in lupus erythematosus lesions using monoclonal antibodies
60. Normal human skin demonstrates marked site‐variation of tenascin, not correlated to epidermal proliferation (Ki‐67 binding)
61. Tenascin expression in human dermis is related to epidermal proliferation
62. The effect of cyclosporin A on proliferation and differentiation‐associated antigens of normal human skin xenografted onto nude mice